Emerging Pathways in COPD: Targeting Inflammation for A Tailored Treatment Approach : Episode 7

Opinion

Video

June 7, 2024

GOLD Treatment Guidelines and Evolving Therapeutic Approaches

Author(s):

Fernando J. Martinez, MD, MS,Nicola Hanania, MD, MS

Experts on respiratory diseases discuss the GOLD treatment guidelines for COPD and discuss research that is informing treatment strategies.

EP: 1.Why is COPD Important?

EP: 2.COPD Traits Associated with Phenotypes

EP: 3.Insights Gleaned from Asthma Research for COPD

EP: 4.Biomarkers in COPD

EP: 5.Unmet Needs in the COPD Treatment Landscape

EP: 6.The Role of Eosinophils in Diagnosing COPD

EP: 7.GOLD Treatment Guidelines and Evolving Therapeutic Approaches

EP: 8.Evolving Treatment Landscape in COPD

EP: 9.Emerging Treatment Approaches in COPD

EP: 10.Future Treatment Landscape for COPD

EP: 11.The Benefits of Earlier Diagnosis and Treatment of COPD

EP: 12.The Relationship Between Comorbidities in COPD

EP: 13.The Role of Primary Care Providers in Managing Patients with COPD

EP: 14.Key Takeaways on the Evolving COPD Treatment Landscape

Can you discuss the initial treatment recommendations (GOLD) Tamondong-Lachica et al 2023
What does the follow up treatment regimen look like?
Discuss the role of triple therapy

Related Videos

Marcelo Kugelmas, MD | Credit: South Denver Gastroenterology

John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates

Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn

Eric Lawitz, MD | Credit: UT Health San Antonio

| Image Credit: X

Ahmad Masri, MD, MS | Credit: Oregon Health and Science University

Ahmad Masri, MD, MS | Credit: Oregon Health and Science University

Stephen Nicholls, MBBS, PhD | Credit: Monash University

Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology

Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University

Related Content

Related Content

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.